Article
Oncology
Georgina Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stephane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Summary: The study investigated the efficacy and safety of Pembrolizumab combined with Ipilimumab in advanced melanoma, demonstrating both regimens had antitumor activity with the lower dose Ipilimumab regimen showing better toxicity profile.
CLINICAL CANCER RESEARCH
(2021)
Article
Dermatology
Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Shunichi Jinnai, Eiji Nakano, Naoya Yamazaki
Summary: The efficacy and safety of nivolumab and ipilimumab combination therapy for advanced melanoma in Japanese patients were re-evaluated. The response rate was higher in patients who had not received prior systemic therapy. However, the efficacy of the combination therapy in Japanese patients appeared to be lower compared to global studies and non-Asian patients.
JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Matthew Tsang, Stephanie Petkiewicz
Summary: In patients with advanced melanoma, pathologist-initiated reflex BRAF testing can reduce laboratory turnaround time and shorten time to systemic treatment, supporting its recommendation as a standard practice in pathology laboratories.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Editorial Material
Oncology
Ryan C. Augustin, Jason J. Luke
Summary: This article discusses the 5-year update of the pivotal trial CheckMate-238 and provides context to its results considering limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Summary: Neoadjuvant concurrent HDI and pembrolizumab therapy showed promising clinical activity in resectable advanced melanoma patients, despite high rates of treatment discontinuation. Pathologic complete response was identified as a prognostic indicator.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano
Summary: Single immune checkpoint blockade has limited efficacy in patients with NENs. However, dual checkpoint blockade with durvalumab and tremelimumab shows promising results in patients with advanced NENs of gastroenteropancreatic and lung origin. This study highlights the potential of durvalumab plus tremelimumab as a treatment option for NENs patients.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fabio Franke, Tudor E. Ciuleanu, Caio Pereira, Eva Munoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbe, Gaelle Quereux, Friedegund Meier, Brendan D. Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A. Tagliaferri, Nikhil I. Khushalani
Summary: Despite the efficacy of Bempegaldesleukin (BEMPEG) in the treatment of melanoma, the PIVOT IO 001 study did not meet its primary end points, with increased toxicity observed with the combination of BEMPEG plus NIVO.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Xue Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit Pallan, Catriona Harvey, Michael P. Manos, Olivia Ouyang, Michelle S. Kim, Gyulnara Kasumova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Tatyana Sharova, Dennie T. Frederick, Keith T. Flaherty, Osama E. Rahma, Georgina V. Long, Alexander M. Menzies, Jun Guo, Alexander N. Shoushtari, Douglas B. Johnson, Ryan J. Sullivan, Genevieve M. Boland
Summary: A multicenter retrospective analysis found that early high-dose GCC use was associated with poorer survival outcomes in melanoma patients after anti-PD-1 monotherapy, highlighting the need for cautious use of GCC. These findings were validated in a combined validation cohort, confirming the association between high-dose GCC use and worse prognosis.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Biochemistry & Molecular Biology
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Alvaro Lopez-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Summary: Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, were evaluated in a multicenter phase 1/2 study for the treatment of recurrent glioblastoma. The combination of intratumoral DNX-2401 followed by intravenous pembrolizumab showed notable survival benefit with an objective response rate of 10.4% and overall survival at 12 months of 52.7%. Exploratory analyses suggested potential predictors of treatment response and resistance. Overall, this combination therapy demonstrated promising results in select patients with glioblastoma.
Article
Oncology
Sandra Martinez-Morilla, Franz Villarroel-Espindola, Pok Fai Wong, Maria Toki, Thazin Nwe Aung, Vasiliki Pelekanou, Brian Bourke-Martin, Kurt A. Schalper, Harriet M. Kluger, David L. Rimm
Summary: The study utilized IMC technology to characterize the tumor microenvironment of patients with metastatic melanoma undergoing immunotherapy, identifying potential indicative biomarkers for treatment response. Through image and multivariable analysis, significant associations with progression-free survival and overall survival were found for specific markers.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Lucia Vazquez-Montero, Maria del Carmen Alamo de la Gala, Luis de la Cruz-Merino
Summary: The development of immune checkpoint inhibitors has transformed the treatment of advanced melanoma. Nivolumab plus ipilimumab, along with other immunotherapy options, has shown efficacy for advanced melanoma. However, the combination therapy is associated with severe immune-related toxicity. This article reviews the efficacy and safety of nivolumab plus ipilimumab in advanced melanoma and explores the potential benefits for different patient subgroups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Olivier J. van Not, Rik J. Verheijden, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion A. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Willeke A. M. Blokx, Michel J. M. Wouters, Karijn P. M. Suijkerbuijk
Summary: This cohort study found that second-line immunosuppression for immune-related adverse events (IRAEs) was associated with impaired progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. These findings emphasize the importance of evaluating the effects of different IRAE management strategies.
Review
Medicine, General & Internal
Mohammad Almohideb
Summary: Nivolumab shows good efficacy in melanoma patients with lower rates of adverse events. Nivolumab monotherapy and its combination with ipilimumab have different survival rates at different time points.
Article
Biochemistry & Molecular Biology
Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloe B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harris, David Y. Chen, Kavita Dhodapkar, Mario Sznol, Ruth Halaban, Aaron M. Newman
Summary: This study provides new insights into the immunological state prior to the development of immune-related adverse events (irAEs) in patients with melanoma treated with immune checkpoint inhibitors (ICIs). The abundance of activated CD4 memory T cells and T cell receptor diversity in the blood samples were found to be associated with severe irAEs, regardless of the affected organ system. The study also investigated the changes in T cell receptor clonality during combination therapy and linked them to the severity and timing of irAE onset. These findings have implications for improved diagnostics and clinical management of irAEs.
Article
Multidisciplinary Sciences
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M. Newman, Ruth Halaban
Summary: Despite being the most common melanoma subtype among non-White individuals, the molecular drivers of acral melanoma remain unknown. In this study, the authors integrated genomic and clinical data from 104 patients and identified recurrent amplifications of cytoband 22q11.21 and LZTR1 as a key tumor promoter in this region.
NATURE COMMUNICATIONS
(2022)
Review
Ophthalmology
Jacob S. Heng, Jenna M. Kim, D. Kyle Jones, Kathleen M. Stoessel, Sarah A. Weiss, Mario Sznol, Harriet M. Kluger, Scott D. Walter, Niki A. Silverstein, Renelle Pointdujour-Lim
Summary: The study aims to demonstrate the spectrum of autoimmune retinopathy (AIR) associated with immunotherapy for advanced cutaneous melanoma. The research found that immune checkpoint inhibitors can trigger the development of AIR in patients with advanced cutaneous melanoma, leading to varied clinical manifestations. The study highlights the importance of close monitoring in cutaneous melanoma patients receiving immunotherapy.
BMJ OPEN OPHTHALMOLOGY
(2022)
Article
Oncology
Malin Hultcrantz, Even H. Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith, Oscar B. Lahoud, Heather J. Landau, Gunjan L. Shah, Michael Scordo, David J. Chung, Sergio Giralt, Elli Papaemmanuil, Ola Landgren
Summary: Using the updated NGS MRD assay, we found a high V(D)J clonotype capture rate in baseline and follow-up samples from patients with multiple myeloma. Additionally, all V(D)J clonotypes detected at baseline were also detected in MRD-positive samples, indicating stable clonotypes without further rearrangements during follow-up.
CLINICAL CANCER RESEARCH
(2022)
Letter
Oncology
Alyce M. Kuo, Hani Hassoun, Urvi Shah, Allison Gordon, Travis J. Hollmann, Heather J. Landau, Cecilia Lezcano, Sham Mailankody, Carlyn C. Tan, Alexander M. Lesokhin, Alina Markova
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Oscar B. Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai, Jonathan Weltz, Tumininu Ayorinde, David J. Chung, Alexander M. Lesokhin, Tarun Kewalramani, Neha Korde, Sham Mailankody, Ola Landgren, Sergio Giralt, Raymond L. Comenzo, Hani Hassoun
Summary: The extended follow-up analysis of a phase 2 trial showed that early responsive patients with newly diagnosed multiple myeloma can safely continue induction therapy without undergoing upfront autologous stem cell transplantation. There were no significant differences in progression-free survival, overall survival, and rates of partial response between the continued induction therapy group and the autologous stem cell transplantation group.
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Matthew J. J. Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P. P. Salvatore, Insara Jaffer-Sathick, Adriana C. C. Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A. A. Shah, Kylee Maclachlan, David J. J. Chung, Gunjan L. L. Shah, Heather J. J. Landau, Neha Korde, Sham Mailankody, Alexander M. M. Lesokhin, Carlyn Tan, Michael Scordo, Edgar A. A. Jaimes, Sergio A. A. Giralt, Saad Usmani, Hani Hassoun
Summary: This retrospective analysis of patients with monoclonal immunoglobulin deposition disease (MIDD) demonstrates that renal response can be captured using both estimated glomerular filtration rate (eGFR) and proteinuria criteria. Most patients achieved a very good partial hematologic response with treatment. Isolated proteinuria may be an early manifestation of MIDD associated with reversible renal damage. Baseline eGFR predicts renal response and survival. Further prospective studies with uniform renal response criteria are needed to optimize the management of MIDD.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M. Totiger, David Coffey, Namrata Chandhok, Justin Watts, Luisa Cimmino, Sydney X. Lu, Niccolo Bolli, Kelly Bolton, Heather Landau, Jae H. Park, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey Tyner, Stephen Nimer, Elli Papaemmanuil, Saad Usmani, Gareth Morgan, Ola Landgren, Francesco Maura
Summary: Through genomic sequencing of 39 therapy-related myeloid malignancies, it was discovered that chemotherapy can accelerate the evolution of cancer cells by inducing mutations and DNA damage. Preleukemic clones (clonal hematopoiesis, CH) that exist before chemotherapy can acquire complex events and genomic drivers after chemotherapy, leading to the development of therapy-related myeloid neoplasms.
Article
Hematology
Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke-Puranik, Gunjan L. Shah, Alexander Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn J. Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
Summary: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has shown remarkable efficacy in relapsed/refractory multiple myeloma patients. However, most patients eventually relapse despite high initial response rates. This study analyzed the salvage treatments and outcomes of patients with disease recurrence after BCMA-directed CAR T therapy.
Letter
Oncology
Urvi A. A. Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J. J. Lee, Sabrin Tahri, Thomas Gwise, Even H. H. Rustad, Sham Mailankody, Alexander M. M. Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M. M. Birmann, Saad Z. Z. Usmani, Nicole Gormley, Catherine R. R. Marinac, Ola Landgren
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Kylee H. Maclachlan, Tina Bagratuni, Efstathios Kastritis, Bachisio Ziccheddu, Sydney Lu, Venkata Yellapantula, Chris Famulare, Kimon Argyropoulos, Andriy Derkach, Elli Papaemmanuil, Ahmet Dogan, Alexander Lesokhin, Saad Z. Usmani, C. Ola Landgren, Lia M. Palomba, Francesco Maura, Meletios A. Dimopoulos
Summary: The genomic landscape of Waldenstrom macroglobulinemia (WM) is characterized by MYD88 somatic mutations which are present from precursor stages. Analysis shows sustained activity of germinal center (GC) mutational signatures, suggesting continued interaction between WM and GC. Copy number aberrations (CNA) progressively increase in symptomatic WM and relapsed disease, with MYD88 wild-type cases often demonstrating early chromosomal gains and later subclonal CNA changes. This suggests that CNA may contribute to progression risk from precursor conditions to symptomatic disease.
Review
Oncology
Urvi A. Shah, Richa Parikh, Francesca Castro, Matteo Bellone, Alexander M. Lesokhin
Summary: This article provides a detailed review of the role of dietary and microbiome factors in the pathogenesis of multiple myeloma (MM) and their impact on outcomes. The findings suggest that dietary and lifestyle interventions may have significant implications for preventing and improving the quality of life of MM patients.
Article
Oncology
Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella, Lionel Karlin, Jean-Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al-Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lepine, Sandrine Mace, Philippe Moreau
Summary: This study aimed to determine whether cemiplimab enhances the anti-myeloma activity of isatuximab in RRMM patients and evaluate its safety. The results showed that although the combination of cemiplimab and isatuximab had a certain effect in patients, the differences were not statistically significant and did not improve progression-free or overall survival. Therefore, adding cemiplimab to the isatuximab treatment regimen only has marginal benefits.
Article
Medicine, General & Internal
Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L. Smith, Malin Hultcrantz, Urvi Shah, Carlyn Tan, Benjamin Diamond, Gunjan Shah, Michael Scordo, Oscar Lahoud, David J. Chung, Heather Landau, Sergio Giralt, Andriy Derkach, Thomas M. Atkinson, Paul Sabbatini, Francesca Konig, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin
Summary: This study monitored the activity levels and quality of life of patients with multiple myeloma (MM) using wearable devices and electronic patient reported outcome (ePRO) tools. The results showed that overall activity levels increased over time, especially in older patients, and were correlated with quality of life measurements. The study demonstrates that monitoring with wearable devices is feasible but challenging in newly diagnosed MM patients.